JPWO2021064137A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021064137A5 JPWO2021064137A5 JP2022520371A JP2022520371A JPWO2021064137A5 JP WO2021064137 A5 JPWO2021064137 A5 JP WO2021064137A5 JP 2022520371 A JP2022520371 A JP 2022520371A JP 2022520371 A JP2022520371 A JP 2022520371A JP WO2021064137 A5 JPWO2021064137 A5 JP WO2021064137A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antigen
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical group 0.000 claims 60
- 239000000427 antigen Substances 0.000 claims 29
- 102000036639 antigens Human genes 0.000 claims 29
- 108091007433 antigens Proteins 0.000 claims 29
- 235000018102 proteins Nutrition 0.000 claims 25
- 102000004169 proteins and genes Human genes 0.000 claims 25
- 108090000623 proteins and genes Proteins 0.000 claims 25
- 101100460850 Homo sapiens NCR3LG1 gene Proteins 0.000 claims 7
- 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 claims 7
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 235000004279 alanine Nutrition 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940121647 egfr inhibitor Drugs 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 230000011278 mitosis Effects 0.000 claims 1
- 230000017205 mitotic cell cycle checkpoint Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023194494A JP2024020414A (ja) | 2019-10-02 | 2023-11-15 | 癌処置のための多重特異性結合タンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19201200 | 2019-10-02 | ||
| EP19201200.3 | 2019-10-02 | ||
| PCT/EP2020/077586 WO2021064137A2 (en) | 2019-10-02 | 2020-10-01 | Multi-specific binding proteins for cancer treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023194494A Division JP2024020414A (ja) | 2019-10-02 | 2023-11-15 | 癌処置のための多重特異性結合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022551081A JP2022551081A (ja) | 2022-12-07 |
| JPWO2021064137A5 true JPWO2021064137A5 (xx) | 2022-12-27 |
| JP7387885B2 JP7387885B2 (ja) | 2023-11-28 |
Family
ID=68136317
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520371A Active JP7387885B2 (ja) | 2019-10-02 | 2020-10-01 | 癌処置のための多重特異性結合タンパク質 |
| JP2023194494A Pending JP2024020414A (ja) | 2019-10-02 | 2023-11-15 | 癌処置のための多重特異性結合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023194494A Pending JP2024020414A (ja) | 2019-10-02 | 2023-11-15 | 癌処置のための多重特異性結合タンパク質 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11732045B2 (xx) |
| EP (1) | EP4038100A2 (xx) |
| JP (2) | JP7387885B2 (xx) |
| KR (1) | KR20220075383A (xx) |
| CN (1) | CN114641496A (xx) |
| AR (1) | AR120138A1 (xx) |
| AU (1) | AU2020358893A1 (xx) |
| BR (1) | BR112022004047A2 (xx) |
| CA (1) | CA3153372A1 (xx) |
| CL (1) | CL2022000664A1 (xx) |
| CO (1) | CO2022003552A2 (xx) |
| CR (1) | CR20220136A (xx) |
| EC (1) | ECSP22019193A (xx) |
| IL (1) | IL291817A (xx) |
| JO (1) | JOP20220079A1 (xx) |
| MX (1) | MX2022004042A (xx) |
| PE (1) | PE20221412A1 (xx) |
| TW (1) | TW202128756A (xx) |
| WO (1) | WO2021064137A2 (xx) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230162013A (ko) | 2021-03-26 | 2023-11-28 | 이나뜨 파르마 에스.에이. | Nk 세포 관여를 위해 사이토카인에 융합된 nkp46-결합 부위, 암 항원 결합 부위를 포함하는 다중특이적 단백질 |
| US12065427B2 (en) | 2021-04-29 | 2024-08-20 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating STING |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| EP4352098A1 (en) | 2021-06-09 | 2024-04-17 | Innate Pharma | Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| CN114395047B (zh) * | 2021-12-07 | 2023-11-07 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
| CN114395043B (zh) * | 2021-12-07 | 2023-07-11 | 合肥天港免疫药物有限公司 | Ncr3lg1抗体及其应用 |
| CN114395045B (zh) * | 2021-12-07 | 2023-06-09 | 合肥天港免疫药物有限公司 | B7h6抗体及其应用 |
| WO2024089006A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
| WO2024088991A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
| WO2024089008A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US168A (en) | 1837-04-17 | Improvement in fire-arms | ||
| US5731A (en) | 1848-08-22 | Elisha k | ||
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5664905A (en) | 1992-08-10 | 1997-09-09 | Alcan Aluminium Uk Limited | Fence |
| EP1621554B2 (en) | 1992-08-21 | 2012-08-29 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US6193969B1 (en) | 1993-06-03 | 2001-02-27 | Protherics Inc. | Antibody fragments in therapy |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| RU2420537C2 (ru) | 2001-01-17 | 2011-06-10 | Трабьон Фармасьютикалз Инк. | Слитые белки связывающий домен-иммуноглобулин |
| US20050214857A1 (en) | 2001-12-11 | 2005-09-29 | Algonomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
| NL1019562C2 (nl) | 2001-12-13 | 2003-06-17 | Heineken Tech Services | Klepsamenstel voor gebruik bij drankafgifte. |
| US8764654B2 (en) | 2008-03-19 | 2014-07-01 | Zin Technologies, Inc. | Data acquisition for modular biometric monitoring system |
| KR101472250B1 (ko) | 2005-10-12 | 2014-12-11 | 모르포시스 아게 | 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링 |
| AU2008308509B2 (en) | 2007-10-04 | 2014-10-23 | Zymogenetics, Inc. | B7 family member zB7H6 and related compositions and methods |
| EP2235064B1 (en) | 2008-01-07 | 2015-11-25 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| FI20090280A (fi) | 2009-07-17 | 2011-01-18 | Kone Corp | Hissijärjestely ja menetelmä hissikorin liikuttamiseksi hissikuilussa |
| BR112012017051A2 (pt) | 2009-12-23 | 2017-12-05 | Esbatech Alcon Biomed Res Unit | método para diminuir a imunogenicidade |
| SG10201509588TA (en) * | 2011-05-21 | 2015-12-30 | Macrogenics Inc | CD3-Binding Molecules Capable Of Binding To Human And Non-Human CD3 |
| MX350074B (es) | 2011-06-23 | 2017-08-25 | Ablynx Nv | Tecnicas para predecir, detectar, y reducir la interferencia de proteinas no especificas en ensayos que implican dominios variables individuales de inmunoglobulina. |
| MX2014001883A (es) | 2011-08-17 | 2014-05-27 | Glaxo Group Ltd | Proteinas y peptidos modificados. |
| DK2766392T3 (da) * | 2011-10-10 | 2019-10-07 | Xencor Inc | Fremgangsmåde til oprensning af antistoffer |
| US9790278B2 (en) * | 2012-05-07 | 2017-10-17 | The Trustees Of Dartmouth College | Anti-B7-H6 antibody, fusion proteins, and methods of using the same |
| CN104640561A (zh) * | 2012-07-23 | 2015-05-20 | 酵活有限公司 | 包含轻链和重链的选择性配对的免疫球蛋白构建体 |
| AU2017238172B2 (en) * | 2016-03-21 | 2024-06-27 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| US11034767B2 (en) | 2016-04-15 | 2021-06-15 | Trustees Of Dartmouth College | High affinity B7-H6 antibodies and antibody fragments |
| RS61510B1 (sr) | 2016-05-18 | 2021-03-31 | Boehringer Ingelheim Int | Anti pd-1 i anti-lag3 antitela za lečenje kancera |
| AU2019280900A1 (en) * | 2018-06-09 | 2020-11-19 | Boehringer Ingelheim International Gmbh | DLL3-CD3 bispecific antibodies |
-
2020
- 2020-09-30 TW TW109134076A patent/TW202128756A/zh unknown
- 2020-10-01 KR KR1020227014608A patent/KR20220075383A/ko unknown
- 2020-10-01 EP EP20789508.7A patent/EP4038100A2/en active Pending
- 2020-10-01 CA CA3153372A patent/CA3153372A1/en active Pending
- 2020-10-01 AR ARP200102733A patent/AR120138A1/es unknown
- 2020-10-01 CR CR20220136A patent/CR20220136A/es unknown
- 2020-10-01 MX MX2022004042A patent/MX2022004042A/es unknown
- 2020-10-01 JO JOP/2022/0079A patent/JOP20220079A1/ar unknown
- 2020-10-01 CN CN202080068909.4A patent/CN114641496A/zh active Pending
- 2020-10-01 IL IL291817A patent/IL291817A/en unknown
- 2020-10-01 JP JP2022520371A patent/JP7387885B2/ja active Active
- 2020-10-01 WO PCT/EP2020/077586 patent/WO2021064137A2/en active Application Filing
- 2020-10-01 US US17/060,111 patent/US11732045B2/en active Active
- 2020-10-01 AU AU2020358893A patent/AU2020358893A1/en active Pending
- 2020-10-01 PE PE2022000468A patent/PE20221412A1/es unknown
- 2020-10-01 BR BR112022004047A patent/BR112022004047A2/pt unknown
-
2022
- 2022-03-14 EC ECSENADI202219193A patent/ECSP22019193A/es unknown
- 2022-03-18 CL CL2022000664A patent/CL2022000664A1/es unknown
- 2022-03-25 CO CONC2022/0003552A patent/CO2022003552A2/es unknown
-
2023
- 2023-06-20 US US18/337,693 patent/US20230340130A1/en active Pending
- 2023-11-15 JP JP2023194494A patent/JP2024020414A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ma et al. | Bispecific antibodies: from research to clinical application | |
| Fischer et al. | Bispecific antibodies: molecules that enable novel therapeutic strategies | |
| CN113260379B (zh) | 蛋白酶可切割的双特异性抗体及其用途 | |
| JP2019533441A5 (xx) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2019502712A5 (xx) | ||
| JP2021098732A5 (xx) | ||
| Müller et al. | Bispecific antibodies | |
| JPWO2019129221A5 (xx) | ||
| JP2018502050A5 (xx) | ||
| Xiong et al. | Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20× anti-CD3 bispecific diabody | |
| JP2022551081A (ja) | 癌処置のための多重特異性結合タンパク質 | |
| MX2008010561A (es) | Anticuerpos funcionales. | |
| JPWO2019234220A5 (xx) | ||
| JP2021507698A5 (xx) | ||
| IL292780A (en) | A new 4-1bbl trimer containing antigen-binding molecules | |
| JPWO2021064137A5 (xx) | ||
| JP2022521305A (ja) | 抗ｐｄ－ｌ１抗体及びその使用 | |
| WO2021113748A1 (en) | Composition of triaxial antibodies and method of making and using thereof | |
| JPWO2019157366A5 (xx) | ||
| JPWO2022102768A5 (xx) | ||
| JPWO2022042488A5 (xx) | ||
| WO2022127066A1 (zh) | 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途 | |
| JPWO2019204564A5 (xx) | ||
| JP2024521701A (ja) | 抗ｃｄ１３７抗体及びその使用方法 |